| 产品描述: | Bemnifosbuvir 是一种有效的具有口服活性的 HCV 病毒复制抑制剂。Bemnifosbuvir 有效抑制 SARS-CoV-2 (COVID-19) 感染 (EC90=0.47 μM)。Bemnifosbuvir 具有全基因型抗病毒活性。 |
| 靶点: |
EC50: 5-28 nM (HCV),EC90: 0.47 μM (SARS-CoV-2);HCVProtease;SARS-CoV |
| 体外研究: |
Bemnifosbuvir has pan-genotypic antiviral activities that inhibits HCV genotype 1a (HCV GT1a), HCV GT1b, HCV GT2a, HCV GT3a, HCV GT4a, and HCV GT5a replication with EC50 values of 12.8 nM, 12.5 nM, 9.2 nM, 10.3 nM, 14.7 nM, and 28.5 nM, respectively. In normal human airway epithelial cells, the concentration of Bemnifosbuvir required to inhibit replication of SARS-CoV-2 by EC90 is 0.47 μM, very similar to its EC90 against HCoV-229E, HCoV-OC43 and SARS-CoV in Huh-7 cells. |
| 体内研究: |
When given orally to rats (500 mg/kg) and monkeys (30 mg/kg, 100 mg/kg or 300 mg/kg), Bemnifosbuvir preferentially delivers high levels of AT-9010 in the liver in vivo. |
| 参考文献: |
1. Steven S Good, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020 Jan 8;15(1):e0227104.
2. Steven S Good, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 2021 Feb 8;AAC.02479-20.
3. Elina Berliba, et al. Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019 Sep 30;63(12):e01201-19. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.72 ml |
8.598 ml |
17.196 ml |
| 5 mM |
0.344 ml |
1.72 ml |
3.439 ml |
| 10 mM |
0.172 ml |
0.86 ml |
1.72 ml |
| 50 mM |
0.034 ml |
0.172 ml |
0.344 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |